Evotec, Dana-Farber Partner on Cancer Epigenetics Drug Development
Investigators at the Dana-Farber Cancer Institute’s Belfer Institute for Applied Cancer Science and Evotec are working together to discover and commercialize cancer treatments based on epigenetic drug mechanisms, the organizations announced today.
Together, Dana-Farber and Evotec hope to validate emerging epigenetic targets for oncology indications and demonstrate the drugability of the selected target families, they said. Financial terms of the agreement were not disclosed.
“This pioneering partnership provides a unique opportunity to combine Evotec's drug discovery capabilities with Belfer Institute for Applied Cancer Science and Dana-Farber Cancer Institute's expertise in oncology disease biology to accelerate the development of new medicines for patients,” Jessie English, head of research at the Belfer Insitute, said in a statement.